Join us as we discuss a recent study of push-up capacity in middle-aged men and the association with CVD risk.
In a recent study, data from the Cardiovascular Health Study examined the association between alcohol consumption and incident HF. It was found that moderate alcohol consumption was associated with a survival benefit, implying that individuals 65 years and older with newly diagnosed HF may not need to stop their alcohol use. Join the discussion about these findings and learn how they may impact the care of your patients with HF.
Managing cholesterol is one of the most common clinical problems. Recently, the American College of Cardiology and the American Heart Association issued new guidance on the management of blood cholesterol. Ten other societies participated in the development of the guidelines. Listen to find out who should be treated with statins, what the treatment targets are, and when other cholesterol-lowering medications should be added.
For patients with established cardiovascular disease,aspirin is clearly beneficial as part of secondary prevention. However, when used as primary prevention in patients without documented cardiovascular disease, its benefit is much less certain. This podcast will explore 3 recent trials that evaluated aspirin in different populations and found nobenefit for its use as primary prevention.
In this episodes, we will discuss a systematic review and meta-analysis that examines outcomes from the use of furosemide compared to torsemide in patients with congestive heart failure.
Alcohol consumption has been associated with negative cardiovascular outcomes, yet many clinicians still counsel patients that it is okay in moderation. Past observational studies have supported this idea, showing a dose-dependent relationship between alcohol consumption and the incidence of a-fib. In this episode we will explore the latest RCT out of Australia, which suggest that no level of alcohol intake is safe when it comes to a-fib.
Obesity, dyslipidemia, and hypertension are significant challenges to public health and impact a growing number of Americans. Weight loss and dietary changes are effective in preventing CVD and DMII and reducing cardiometabolic complications, but can be difficult for many people. Growing evidence supports the use of timed fasting to promote weight loss and reduce these complications. Join us as we discuss a recent study that shows promising data regarding a 10-hour feeding window and improved CV markers.
Join us as we review a landmark paper that reached the conclusion that limiting red meat would not have a large impact on patient outcomes.
In this episode we expand on the rationale for not screening and treating hyperlipidemia in patients without CV disease, diabetes, renal failure or heart failure.
This initiative aims to increase understanding among cardiologists about adjunctive LDL-C-lowering therapies and their potential role in reducing residual ASCVD risk. During this series, national lipid expert faculty will discuss the incidence of and diagnostic criteria for statin intolerance, explain the mechanistic rationale for lowering LDL-C through nonstatin therapies, and explore novel targets and treatment pathways. It is expected to improve cardiologists’ management of patients with ‘tough-to-treat’ cholesterol according to the 2018 American Heart Association (AHA)/American College of Cardiology (ACC)/Multi-society Cholesterol Guidelines. Learners will have the opportunity to gain practical clinical perspectives during expert case study discussions. The patient scenarios will discuss how new treatment options may fit into the current therapeutic landscape.
Adults with type 2 diabetes mellitus (T2DM) have a two- to four-fold increase in risk for cardiovascular (CV) morbidity and mortality. This session cuts to the heart of primary and secondary prevention in this population, presenting recent data on antihyperglycemic medications with proven cardiovascular benefit in the context of updated management algorithms. Individualized treatment is critical to the success of these treatment plans. The faculty will help you optimize adherence through shared decision-making tactics that account for CV risk factors, comorbidities, and patient preferences. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 6/26/2020, and they are subject to change as new information is published.